AR066626A1 - Oligonucleotidos de clase a con potencia inmunoestimuladora - Google Patents

Oligonucleotidos de clase a con potencia inmunoestimuladora

Info

Publication number: AR066626A1
Authority: AR; Argentina
Prior art keywords: oligonucleotides; class; immune stimulating; nucleotide; stimulating power
Prior art date: 2007-05-17

Application number

ARP080102108A

Other languages

English (en)

Spanish (es)

Original Assignee

Coley Pharm Group Inc

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-17

Filing date

2008-05-16

Publication date

2009-09-02

2008-05-16 Application filed by Coley Pharm Group Inc, Coley Pharm Gmbh filed Critical Coley Pharm Group Inc

2009-09-02 Publication of AR066626A1 publication Critical patent/AR066626A1/es

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000004936 stimulating effect Effects 0.000 title 1
239000002773 nucleotide Substances 0.000 abstract 4
125000003729 nucleotide group Chemical group 0.000 abstract 4
230000003308 immunostimulating effect Effects 0.000 abstract 3
LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

ARP080102108A 2007-05-17 2008-05-16 Oligonucleotidos de clase a con potencia inmunoestimuladora AR066626A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US93058007P	2007-05-17	2007-05-17

Publications (1)

Publication Number	Publication Date
AR066626A1 true AR066626A1 (es)	2009-09-02

Family

ID=39720158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP080102108A AR066626A1 (es)	2007-05-17	2008-05-16	Oligonucleotidos de clase a con potencia inmunoestimuladora

Country Status (15)

Country	Link
US (1)	US20100285041A1 (2)
EP (1)	EP2160199A2 (2)
JP (1)	JP2009035530A (2)
KR (1)	KR20100010509A (2)
CN (1)	CN101678098A (2)
AR (1)	AR066626A1 (2)
AU (1)	AU2008252577A1 (2)
BR (1)	BRPI0811621A2 (2)
CA (1)	CA2687441A1 (2)
IL (1)	IL202096A0 (2)
MX (1)	MX2009012482A (2)
RU (1)	RU2009142211A (2)
TW (1)	TW200916115A (2)
WO (1)	WO2008142509A2 (2)
ZA (1)	ZA200908062B (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP3006043B1 (en)	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatory g,u-containing oligoribonucleotides
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
CN1753687A (zh)	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
EP1678303A2 (en)	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-class oligonucleotide analogs with enhanced immunostimulatory potency
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2575878B1 (en) *	2010-05-28	2018-06-13	Zoetis Belgium S.A.	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
EP2471926A3 (en) *	2010-12-30	2012-07-11	Intervet International BV	Immunostimulatory oligodeoxynucleotides
KR102213609B1 (ko) *	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
JP6715775B2 (ja) *	2014-12-25	2020-07-01	国立研究開発法人医薬基盤・健康・栄養研究所	非凝集性免疫賦活化オリゴヌクレオチド
JP6698069B2 (ja) *	2015-03-20	2020-05-27	国立研究開発法人医薬基盤・健康・栄養研究所	免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus
WO2019240504A1 (en) *	2018-06-12	2019-12-19	Am Sciences Co., Ltd.	Modified oligonucleotides for inhibition of target gene expression
KR102273071B1 (ko) *	2018-06-12	2021-07-05	주식회사 에이엠사이언스	B형 간염 예방 또는 치료용 조성물
WO2023034853A2 (en) *	2021-08-31	2023-03-09	City Of Hope	Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
CN113517062B (zh) *	2021-09-14	2021-12-10	青岛未来移动医疗科技有限公司	一种智能疫苗雾化系统及使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3854480A (en) *	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US4469863A (en) *	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
US5023243A (en) *	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4452775A (en) *	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) *	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
DE4321946A1 (de) *	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5658738A (en) *	1994-05-31	1997-08-19	Becton Dickinson And Company	Bi-directional oligonucleotides that bind thrombin
EP1167379A3 (en) *	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5736152A (en) *	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP1003531B1 (en)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
AU760549B2 (en) *	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
PT1187629E (pt) *	1999-04-19	2005-02-28	Glaxosmithkline Biolog Sa	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU783118B2 (en)	1999-09-27	2005-09-29	Coley Pharmaceutical Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
ATE411054T1 (de)	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US20080009455A9 (en) *	2005-02-24	2008-01-10	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
JP2008535859A (ja) *	2005-04-08	2008-09-04	コーリーファーマシューティカルグループ，インコーポレイテッド	感染症によって悪化した喘息を治療するための方法

2008
- 2008-05-15 CA CA002687441A patent/CA2687441A1/en not_active Abandoned
- 2008-05-15 BR BRPI0811621-0A2A patent/BRPI0811621A2/pt not_active IP Right Cessation
- 2008-05-15 EP EP08750940A patent/EP2160199A2/en not_active Withdrawn
- 2008-05-15 RU RU2009142211/15A patent/RU2009142211A/ru not_active Application Discontinuation
- 2008-05-15 MX MX2009012482A patent/MX2009012482A/es unknown
- 2008-05-15 US US12/600,364 patent/US20100285041A1/en not_active Abandoned
- 2008-05-15 CN CN200880016477A patent/CN101678098A/zh active Pending
- 2008-05-15 AU AU2008252577A patent/AU2008252577A1/en not_active Abandoned
- 2008-05-15 KR KR1020097026396A patent/KR20100010509A/ko not_active Ceased
- 2008-05-15 WO PCT/IB2008/001199 patent/WO2008142509A2/en not_active Ceased
- 2008-05-16 AR ARP080102108A patent/AR066626A1/es unknown
- 2008-05-16 JP JP2008129762A patent/JP2009035530A/ja active Pending
- 2008-05-16 TW TW097118306A patent/TW200916115A/zh unknown
2009
- 2009-11-12 IL IL202096A patent/IL202096A0/en unknown
- 2009-11-16 ZA ZA200908062A patent/ZA200908062B/xx unknown

Also Published As

Publication number	Publication date
EP2160199A2 (en)	2010-03-10
BRPI0811621A2 (pt)	2014-10-21
US20100285041A1 (en)	2010-11-11
JP2009035530A (ja)	2009-02-19
AU2008252577A1 (en)	2008-11-27
IL202096A0 (en)	2010-06-16
TW200916115A (en)	2009-04-16
ZA200908062B (en)	2010-06-30
RU2009142211A (ru)	2011-05-27
WO2008142509A2 (en)	2008-11-27
CN101678098A (zh)	2010-03-24
MX2009012482A (es)	2009-12-02
KR20100010509A (ko)	2010-02-01
CA2687441A1 (en)	2008-11-27
WO2008142509A3 (en)	2009-03-05

Legal Events

Date	Code	Title	Description
2014-06-19	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR066626A1 (es)	2009-09-02	Oligonucleotidos de clase a con potencia inmunoestimuladora
ES2618783T3 (es)	2017-06-22	Construcción de ADN inmunomodulador no codificante
NZ563845A (en)	2010-09-30	RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
NZ591416A (en)	2012-11-30	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
NZ599032A (en)	2014-09-26	Modulation of huntingtin expression
MX2011009597A (es)	2012-05-29	Deteccion mejorada de la expresion del gen.
MX2010004452A (es)	2010-08-04	Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
PE20191351A1 (es)	2019-10-01	Tratamiento aav de la enfermedad de huntington
MX346862B (es)	2017-04-04	Secuencias consenso de envoltura de vih y método para usar las mismas.
MX2015001310A (es)	2016-02-03	Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.
PE20090985A1 (es)	2009-08-03	Oligonucleotidos como agentes inmunoestimuladores
WO2009139630A9 (en)	2010-05-06	Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
MX2009003398A (es)	2009-08-12	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
JP2016526529A5 (2)	2017-08-17
MX356830B (es)	2018-06-15	Adyuvante de acido nucleico quiral.
ATE538127T1 (de)	2012-01-15	6-disubstituierte bicyclische nukleinsäureanaloga
EA201490534A1 (ru)	2014-06-30	Способы мечения днк-кодированных библиотек
NZ630591A (en)	2017-02-24	Microrna compounds and methods for modulating mir-21 activity
MX2010004984A (es)	2010-07-29	Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
MX2010003877A (es)	2010-04-30	Analogos de oligonucleotidos inmunoestimuladores que contienen restos de azucar modificados.
NZ607870A (en)	2015-09-25	Lactococcus crispr-cas sequences
MX374553B (es)	2025-03-06	Derivado de ácido nucleico que tiene actividad inmunoestimuladora.
BR112015024764A2 (pt)	2017-10-24	oligonucleotídeos de tgf-beta modificados
MX2018009090A (es)	2019-03-28	Oligonucleótido de cadena simple.
MX2021011019A (es)	2021-10-14	Ligadores de brazo colgante corto para nucleotidos en aplicaciones de secuenciacion.